Literature DB >> 12793948

Survival and renal function in pediatric patients following extracorporeal life support with hemofiltration.

Robyn J. Meyer1, Patrick D. Brophy, Timothy E. Bunchman, Gail M. Annich, Norma J. Maxvold, Theresa A. Mottes, Joseph R. Custer.   

Abstract

OBJECTIVE: To determine variables associated with survival in pediatric patients treated with hemofiltration while receiving extracorporeal life support and to determine the probability for recovery of renal function among survivors.
DESIGN: Retrospective database analysis.
SETTING: University of Michigan pediatric nephrology database. PATIENTS: All pediatric patients treated with continuous hemofiltration while on extracorporeal life support at the University of Michigan between January 1990 and May 1999. A pediatric patient was defined as any child between birth and 18 yrs of age, including children treated in both the pediatric intensive care unit and neonatal intensive care unit. Indications for extracorporeal life support included both cardiac and pulmonary failure.
INTERVENTIONS: Data analysis of patients who were treated with hemofiltration while on extracorporeal life support. Hemofiltration includes both ultrafiltration and hemofiltration with countercurrent dialysis.
MEASUREMENTS AND MAIN RESULTS: Thirty-five patients with a mean age of 39 +/- 65 months (median, 3 months) underwent hemofiltration while on extracorporeal life support. Forty-three percent survived to hospital discharge (95% CI, 26%-60%). All deaths occurred in the intensive care unit. Recovery of renal function occurred in 93% of survivors (95% CI, 79%-108%). Mean duration of hemofiltration in survivors, including time during and after extracorporeal life support, was 9 +/- 6 days. All nonsurvivors were on renal replacement therapy at the time of death. In this analysis, decreased survival was significantly associated with the use of vasopressor infusions (p =.01) and the presence of complications (p =.006). Vasopressor infusions were required in 89% of patients, and 37% of patients experienced complications.
CONCLUSIONS: In patients receiving hemofiltration while on extracorporeal life support, survival is comparable to that reported in other extracorporeal life support or hemofiltration populations. Decreased survival in these patients may be associated with the use of vasopressor infusions and the occurrence of complications. Recovery of renal function occurs in most survivors.

Entities:  

Year:  2001        PMID: 12793948     DOI: 10.1097/00130478-200107000-00009

Source DB:  PubMed          Journal:  Pediatr Crit Care Med        ISSN: 1529-7535            Impact factor:   3.624


  20 in total

1.  Recovery of renal function and survival after continuous renal replacement therapy during extracorporeal membrane oxygenation.

Authors:  Matthew L Paden; Barry L Warshaw; Micheal L Heard; James D Fortenberry
Journal:  Pediatr Crit Care Med       Date:  2011-03       Impact factor: 3.624

2.  A multicenter international survey of renal supportive therapy during ECMO: the Kidney Intervention During Extracorporeal Membrane Oxygenation (KIDMO) group.

Authors:  Geoffrey M Fleming; David J Askenazi; Brian C Bridges; David S Cooper; Mathew L Paden; David T Selewski; Michael Zappitelli
Journal:  ASAIO J       Date:  2012 Jul-Aug       Impact factor: 2.872

Review 3.  The evolution of patient selection criteria and indications for extracorporeal life support in pediatric cardiopulmonary failure: next time, let's not eat the bones.

Authors:  Joseph R Custer
Journal:  Organogenesis       Date:  2011-01-01       Impact factor: 2.500

Review 4.  Continuous renal replacement therapy in children.

Authors:  Scott M Sutherland; Steven R Alexander
Journal:  Pediatr Nephrol       Date:  2012-02-28       Impact factor: 3.714

5.  Impact of Kidney Disease on Survival in Neonatal Extracorporeal Life Support.

Authors:  Aaron Wightman; Miranda C Bradford; Jordan Symons; Thomas V Brogan
Journal:  Pediatr Crit Care Med       Date:  2015-07       Impact factor: 3.624

6.  Fluid overload and fluid removal in pediatric patients on extracorporeal membrane oxygenation requiring continuous renal replacement therapy.

Authors:  David T Selewski; Timothy T Cornell; Neal B Blatt; Yong Y Han; Theresa Mottes; Mallika Kommareddi; Michael G Gaies; Gail M Annich; David B Kershaw; Thomas P Shanley; Michael Heung
Journal:  Crit Care Med       Date:  2012-09       Impact factor: 7.598

7.  CKD and hypertension during long-term follow-up in children and adolescents previously treated with extracorporeal membrane oxygenation.

Authors:  Alexandra J M Zwiers; Hanneke IJsselstijn; Joost van Rosmalen; Saskia J Gischler; Saskia N de Wildt; Dick Tibboel; Karlien Cransberg
Journal:  Clin J Am Soc Nephrol       Date:  2014-10-02       Impact factor: 8.237

8.  The Incidence of Acute Kidney Injury and Its Effect on Neonatal and Pediatric Extracorporeal Membrane Oxygenation Outcomes: A Multicenter Report From the Kidney Intervention During Extracorporeal Membrane Oxygenation Study Group.

Authors:  Geoffrey M Fleming; Rashmi Sahay; Michael Zappitelli; Eileen King; David J Askenazi; Brian C Bridges; Matthew L Paden; David T Selewski; David S Cooper
Journal:  Pediatr Crit Care Med       Date:  2016-12       Impact factor: 3.624

9.  Enhanced fluid management with continuous venovenous hemofiltration in pediatric respiratory failure patients receiving extracorporeal membrane oxygenation support.

Authors:  Nancy G Hoover; Michael Heard; Christopher Reid; Scott Wagoner; Kristine Rogers; Jason Foland; Matthew L Paden; James D Fortenberry
Journal:  Intensive Care Med       Date:  2008-07-15       Impact factor: 17.440

10.  Fluid overload and fluid removal in pediatric patients on extracorporeal membrane oxygenation requiring continuous renal replacement therapy: a multicenter retrospective cohort study.

Authors:  Stephen M Gorga; Rashmi D Sahay; David J Askenazi; Brian C Bridges; David S Cooper; Matthew L Paden; Michael Zappitelli; Katja M Gist; Jason Gien; Rajit K Basu; Jennifer G Jetton; Heidi J Murphy; Eileen King; Geoffrey M Fleming; David T Selewski
Journal:  Pediatr Nephrol       Date:  2020-01-17       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.